These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30854983)

  • 1. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
    Huang L; Wells MC; Zhao Z
    Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of P-Glycoprotein-Mediated Active Efflux on Drug Distribution into Lumbar Cerebrospinal Fluid in Nonhuman Primates.
    Nagaya Y; Katayama K; Kusuhara H; Nozaki Y
    Drug Metab Dispos; 2020 Nov; 48(11):1183-1190. PubMed ID: 32862147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
    Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
    Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
    Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
    Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
    Sato S; Matsumiya K; Tohyama K; Kosugi Y
    AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.
    Patel NC; Feng B; Hou X; West MA; Trapa PE; Sciabola S; Verhoest P; Liras JL; Maurer TS; Wager TT
    ACS Chem Neurosci; 2021 Mar; 12(6):1007-1017. PubMed ID: 33651587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
    Chatterjee S; Deshpande AA; Shen H
    Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
    Gupta M; Feng J; Bhisetti G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of utility of cerebrospinal fluid drug concentration as a surrogate for interstitial fluid concentration using microdialysis coupled with cisternal cerebrospinal fluid sampling in wild-type and Mdr1a(-/-) rats.
    Nagaya Y; Nozaki Y; Takenaka O; Watari R; Kusano K; Yoshimura T; Kusuhara H
    Drug Metab Pharmacokinet; 2016 Feb; 31(1):57-66. PubMed ID: 26830080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ATP-Binding Cassette Transporter-Mediated Efflux Transport of Ganciclovir at the Blood-Brain Barrier.
    Shan Y; Cen Y; Xu X; Li P; Chen J; Nie Z; Zhang J
    Eur J Drug Metab Pharmacokinet; 2024 Sep; 49(5):609-617. PubMed ID: 38963639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF as a surrogate for assessing CNS exposure: an industrial perspective.
    Lin JH
    Curr Drug Metab; 2008 Jan; 9(1):46-59. PubMed ID: 18220571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
    Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
    Kalvass JC; Maurer TS; Pollack GM
    Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropharmacokinetics of two investigational compounds in rats: divergent temporal profiles in the brain and cerebrospinal fluid.
    Tang C; Chen T; Kapadnis S; Hodgdon H; Tao Y; Chen X; Wen M; Costa D; Murphy D; Nolan S; Flood DG; Welty DF; Koenig G
    Biochem Pharmacol; 2014 Oct; 91(4):543-51. PubMed ID: 25091561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
    Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
    Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.